Gossamer Bio, Inc. (GOSS) shareholders
Close on Nov 17, 2026Market cap $5.40BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Ari Zweiman Joint filing with 683 Capital Management, LLC (9.99%), 683 Capital Partners, LP (9.99%) | 49,868,571 | 9.99% | 13G (passive) | Jun 4, 2026 |
| Michael S. Rosen Joint filing with Context Capital Management, LLC (9.90%), William D. Fertig (9.90%) and 2 more | 48,835,788 | 9.90% | 13G (passive) | Jun 4, 2026 |
| DeepCurrents Investment Group LLC Joint filing with Kai Zheng (7.70%), Dcig Gp LLC (5.70%) and 1 more | 37,665,073 | 7.70% | 13G (passive) | Jun 4, 2026 |
| Invus Public Equities Advisors, LLC Joint filing with Invus Public Equities, L.P. (5.80%), Artal International S.C.A (5.80%) and 5 more | 13,108,880 | 5.80% | 13G (passive) | Dec 14, 2023 |
| FMR LLC Joint filing with Abigail P. Johnson (10.90%) | 667,465 | 10.90% | 13G (passive) | Oct 30, 2026 |
| Opaleye Management Inc. Joint filing with James Silverman (6.98%), Opaleye, L.P. (6.79%) | 426,989 | 6.98% | 13G (passive) amendment | Sep 30, 2026 |
| D. E. Shaw & Co., L.P. Joint filing with D. E. Shaw & Co., L.L.C. (5.10%), David E. Shaw (5.10%) | 312,048 | 5.10% | 13D (active) amendment | Sep 24, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of GOSS | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| D. E. Shaw & Co., Inc. | 511,991 | 0.10% | $6.74M | +507,123 | 0.00% |
| 683 Capital Management, LLC | 489,986 | 0.10% | $6.45M | +427,486 | 0.32% |
| DeepCurrents Investment Group LLC | 470,814 | 0.10% | $6.03M | New | 0.18% |
| Context Capital Management, LLC | 361,831 | 0.07% | $4.76M | New | 0.09% |
| Worth Venture Partners, LLC | 312,724 | 0.06% | $4.12M | New | 9.29% |
| Kalehua Capital Management LLC | 278,734 | 0.06% | $3.67M | +57,382 | 1.17% |
| Aqr Capital Management LLC | 195,375 | 0.04% | $2.57M | +68,788 | 0.00% |
| Gsa Capital Partners Llp | 187,337 | 0.04% | $2.47M | +146,659 | 0.16% |
| Wolverine Asset Management LLC | 161,184 | 0.03% | $2.12M | New | 0.02% |
| Renaissance Technologies LLC | 145,374 | 0.03% | $1.91M | +130,151 | 0.00% |
| Vanguard Capital Management LLC | 117,700 | 0.02% | $1.55M | +268 | 0.00% |
| ARCH Venture Management, LLC | 100,699 | 0.02% | $1.33M | – | 0.12% |
| Barclays PLC | 97,907 | 0.02% | $1.29M | +59,585 | 0.00% |
| Octagon Capital Advisors LP | 96,875 | 0.02% | $1.28M | – | 0.11% |
| BlackRock, Inc. | 95,875 | 0.02% | $1.26M | −114,460 | 0.00% |
| Arrowstreet Capital, Limited Partnership | 94,667 | 0.02% | $1.25M | New | 0.00% |
| Two Sigma Investments, LP | 92,900 | 0.02% | $1.22M | +33,139 | 0.00% |
| Samsara BioCapital, LLC | 90,282 | 0.02% | $1.19M | – | 0.10% |
| Qube Research & Technologies Ltd | 88,322 | 0.02% | $1.16M | +26,850 | 0.00% |
| Corient Private Wealth LLC | 70,409 | 0.01% | $927.14K | +20,592 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 170 | 5M | 1.0% | 28 / 63 | 44 / 42 | 3M | 0M |
| Q1 2026 | 185 | 2M | 0.5% | 47 / 71 | 49 / 54 | 1M | 1M |
| Q4 2025 | 195 | 2M | 0.5% | 49 / 69 | 48 / 14 | 0M | 0M |
| Q3 2025 | 164 | 2M | 0.5% | 56 / 47 | 44 / 14 | 0M | 0M |
| Q2 2025 | 123 | 2M | 0.5% | 33 / 41 | 24 / 28 | 0M | 0M |
| Q1 2025 | 118 | 2M | 0.4% | 23 / 34 | 30 / 9 | 0M | 0M |
| Q4 2024 | 105 | 2M | 0.4% | 18 / 32 | 27 / 13 | 0M | 0M |
| Q3 2024 | 100 | 2M | 0.4% | 17 / 24 | 30 / 10 | 0M | 0M |
| Q2 2024 | 94 | 2M | 0.5% | 11 / 33 | 29 / 26 | 0M | 1M |
| Q1 2024 | 109 | 3M | 0.5% | 26 / 27 | 31 / 15 | 0M | 0M |
| Q4 2023 | 98 | 3M | 0.6% | 22 / 33 | 22 / 19 | 1M | 1M |
| Q3 2023 | 95 | 3M | 0.5% | 31 / 31 | 18 / 34 | 2M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
111 funds held GOSS in Q1 2026, 73% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of GOSS | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 6,910,934 | 1.41% | $1.14M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 2,243,305 | 0.46% | $369.25K | 0.00% | Jun 30, 2026 |
| iShares Biotechnology ETF | 1,501,116 | 0.31% | $247.08K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 1,150,857 | 0.24% | $265.73K | 0.00% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 986,826 | 0.20% | $227.86K | 0.00% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 977,030 | 0.20% | $225.60K | 0.00% | May 31, 2026 |
| Invesco RAFI US 1500 Small-Mid ETF | 556,395 | 0.11% | $94.31K | 0.00% | Jul 31, 2026 |
| Vanguard Health Care Index Fund | 541,950 | 0.11% | $125.14K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 381,135 | 0.08% | $88.00K | 0.00% | May 31, 2026 |
| BlackRock Health Sciences Opportunities Portfolio | 365,199 | 0.07% | $84.32K | 0.00% | May 29, 2026 |
| Fidelity Series Total Market Index Fund | 300,421 | 0.06% | $69.37K | 0.00% | May 31, 2026 |
| iShares Core S&P Total U.S. Stock Market ETF | 294,007 | 0.06% | $48.39K | 0.00% | Jun 30, 2026 |
| Goldman Sachs Absolute Return Tracker Fund | 267,245 | 0.05% | $43.99K | 0.00% | Jun 30, 2026 |
| Eventide Small Cap ETF | 204,551 | 0.04% | $34.67K | 0.10% | Jul 31, 2026 |
| Vanguard Russell 2000 Growth Index Fund | 180,256 | 0.04% | $41.62K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Faheem Hasnain | President & CEO, Director | 6,245,866 | 1.28% | Aug 26, 2026 |
| Caryn Peterson | Chief Development Officer | 259,333 | 0.05% | Aug 26, 2026 |
| Waage Christian | EVP, Tech Ops and Admin | 882,175 | 0.18% | Aug 26, 2026 |
| Bryan Giraudo | COO/CFO | 869,747 | 0.18% | Aug 26, 2026 |
| Robert Paul Smith JR | Chief Commercial Officer | 285,898 | 0.06% | Aug 26, 2026 |
| Richard Aranda | Chief Medical Officer | 465,645 | 0.10% | Mar 20, 2026 |
| Russell J. Cox | Director | 7,200 | 0.00% | Sep 25, 2026 |
| John D. Quisel | Director | – | – | Sep 25, 2026 |
| Gregory Austin Ciongoli | Director | – | – | Sep 25, 2026 |
| Skye Drynan | Director | – | – | Sep 25, 2026 |
| Sandra Milligan | Director | 90,050 | 0.02% | Sep 25, 2026 |
| Steven D. Nathan | Director | – | – | Sep 25, 2026 |
| Thomas O. Daniel | Director | 38,095 | 0.01% | Sep 25, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Robert Paul Smith JR Chief Commercial Officer | Jan 2, 2026 | Award | +93,750 | – | – | 260,898 |
| Caryn Peterson EVP, Regulatory Affairs | Jan 2, 2026 | Award | +84,500 | – | – | 259,333 |
| Richard Aranda Chief Medical Officer | Jan 2, 2026 | Award | +93,750 | – | – | 463,106 |
| Faheem Hasnain President & CEO, Director | Jan 2, 2026 | Award | +280,000 | – | – | 837,793 |
| Waage Christian EVP, Tech Ops and Admin | Jan 2, 2026 | Award | +84,500 | – | – | 814,061 |
| Bryan Giraudo COO/CFO | Jan 2, 2026 | Award | +115,750 | – | – | 389,737 |
| Faheem Hasnain President & CEO, Director | Oct 1, 2025 | Award | +437,500 | – | – | 557,793 |
| Richard Aranda Chief Medical Officer | Oct 1, 2025 | Award | +162,500 | – | – | 369,356 |
| Caryn Peterson EVP, Regulatory Affairs | Oct 1, 2025 | Award | +125,000 | – | – | 174,833 |
| Bryan Giraudo COO/CFO | Oct 1, 2025 | Award | +181,250 | – | – | 273,987 |
| Robert Paul Smith JR Chief Commercial Officer | Oct 1, 2025 | Award | +162,500 | – | – | 162,500 |
| Waage Christian EVP, Tech Ops and Admin | Oct 1, 2025 | Award | +125,000 | – | – | 710,934 |
| Sandra Milligan Director | Aug 19, 2025 | Buy | +26,050 | $1.92 | $50.02K | 58,050 |
| Richard Aranda Chief Medical Officer | Jun 24, 2024 | Sale | −1,908 | $0.66 | $1.26K | 196,891 |
| Faheem Hasnain President & CEO, Director | Jun 21, 2024 | Buy | +372,000 | $0.67 | $249.24K | 5,408,073 |
| Bryan Giraudo COO/CFO | Jun 18, 2024 | Buy | +100,000 | $0.59 | $59.00K | 480,010 |
| Robert Paul Smith JR Chief Commercial Officer | Jun 17, 2024 | Buy | +25,000 | $0.60 | $15.00K | 25,000 |
| Waage Christian EVP, Tech Ops and Admin | Mar 27, 2024 | Sale | −6,430 | $1.16 | $7.46K | 585,934 |
| Bryan Giraudo COO/CFO | Mar 27, 2024 | Sale | −6,430 | $1.16 | $7.46K | 92,737 |
| Faheem Hasnain President & CEO, Director | Mar 27, 2024 | Sale | −23,172 | $1.16 | $26.88K | 120,293 |
| Richard Aranda Chief Medical Officer | Mar 18, 2024 | Sale | −4,018 | $1.33 | $5.34K | 198,799 |
| Caryn Peterson EVP, Regulatory Affairs | Mar 18, 2024 | Sale | −4,018 | $1.33 | $5.34K | 49,833 |
| Sandra Milligan Director | Nov 15, 2023 | Buy | +32,000 | $0.79 | $25.28K | 32,000 |
| Bryan Giraudo COO/CFO | Nov 13, 2023 | Buy | +200,000 | $0.56 | $112.00K | 380,010 |
| Faheem Hasnain President & CEO, Director | Jul 24, 2023 | Award | +540,176 | $1.82 | $983.12K | 5,036,073 |
| Waage Christian EVP, Tech Ops and Admin | Jul 24, 2023 | Award | +13,504 | $1.82 | $24.58K | 45,892 |
| Bryan Giraudo COO/CFO | Jul 24, 2023 | Award | +54,020 | $1.82 | $98.32K | 180,010 |
| Richard Aranda Chief Medical Officer | Jun 22, 2023 | Sale | −1,814 | $1.29 | $2.34K | 197,574 |
| Bryan Giraudo COO/CFO | Apr 4, 2023 | Buy | +55,000 | $1.02 | $56.10K | 125,990 |
| Faheem Hasnain President & CEO, Director | Mar 22, 2023 | Buy | +440,500 | $1.14 | $502.17K | 4,495,897 |
| Faheem Hasnain President & CEO, Director | Mar 21, 2023 | Buy | +269,389 | $1.20 | $323.27K | 4,055,397 |
| Waage Christian EVP, Tech Ops and Admin | Mar 20, 2023 | Buy | +18,500 | $1.20 | $22.20K | 32,388 |
| Faheem Hasnain President & CEO, Director | Mar 20, 2023 | Buy | +168,683 | $1.03 | $173.74K | 3,786,008 |
| Bryan Giraudo COO/CFO | Mar 20, 2023 | Buy | +50,000 | $0.97 | $48.50K | 70,990 |
| Caryn Peterson EVP, Regulatory Affairs | Mar 16, 2023 | Sale | −7,564 | $1.10 | $8.32K | 53,851 |
| Laura Carter Chief Scientific Officer | Mar 16, 2023 | Sale | −6,029 | $1.10 | $6.63K | 76,263 |
| Richard Aranda Chief Medical Officer | Mar 16, 2023 | Sale | −7,563 | $1.10 | $8.32K | 199,388 |
| Laura Carter Chief Scientific Officer | Oct 24, 2022 | Sale | −4,876 | $12.07 | $58.85K | 82,292 |
| Caryn Peterson EVP, Regulatory Affairs | Oct 24, 2022 | Sale | −4,757 | $12.07 | $57.42K | 61,415 |
| Richard Aranda Chief Medical Officer | Oct 24, 2022 | Sale | −4,757 | $12.07 | $57.42K | 205,430 |
| Laura Carter Chief Scientific Officer | Oct 24, 2022 | Sale | −4,876 | $12.07 | $58.85K | 82,292 |
| Laura Carter Chief Scientific Officer | Jul 15, 2022 | Buy | +6,934 | $7.21 | $49.99K | 87,168 |
| Waage Christian EVP, Tech Ops and Admin | Jul 15, 2022 | Buy | +6,934 | $7.21 | $49.99K | 13,888 |
| Bryan Giraudo COO/CFO | Jul 15, 2022 | Buy | +13,869 | $7.21 | $100.00K | 20,990 |
| Faheem Hasnain President & CEO, Director | Jul 15, 2022 | Buy | +138,696 | $7.21 | $1,000.00K | 3,617,325 |
| Laura Carter Chief Scientific Officer | Jul 1, 2022 | Sale | −8,808 | $8.25 | $72.67K | 80,234 |
| Richard Aranda Chief Medical Officer | Jun 22, 2022 | Sale | −1,778 | $6.88 | $12.23K | 209,897 |
| Laura Carter Chief Scientific Officer | May 4, 2022 | Sale | −1,262 | $7.20 | $9.09K | 89,042 |
| Waage Christian EVP, Tech Ops and Admin | Mar 23, 2022 | Sale | −10,722 | $8.92 | $95.64K | 579,008 |
| Faheem Hasnain President & CEO, Director | Mar 23, 2022 | Sale | −19,035 | $8.92 | $169.79K | 143,465 |
| Bryan Giraudo COO/CFO | Mar 23, 2022 | Sale | −10,722 | $8.92 | $95.64K | 99,167 |
| Laura Carter Chief Scientific Officer | Mar 16, 2022 | Sale | −5,002 | $8.28 | $41.42K | 90,304 |
| Richard Aranda Chief Medical Officer | Mar 16, 2022 | Sale | −6,278 | $8.28 | $51.98K | 211,675 |
| Caryn Peterson EVP, Regulatory Affairs | Mar 16, 2022 | Sale | −6,279 | $8.28 | $51.99K | 66,172 |
| Laura Carter Chief Scientific Officer | Oct 25, 2021 | Sale | −2,377 | $12.25 | $29.12K | 95,306 |
| Richard Aranda Chief Medical Officer | Oct 25, 2021 | Sale | −2,377 | $12.25 | $29.12K | 217,432 |
| Caryn Peterson EVP, Regulatory Affairs | Oct 25, 2021 | Sale | −2,377 | $12.25 | $29.12K | 72,451 |
| Laura Carter Chief Scientific Officer | Jun 30, 2021 | Award | +25,000 | – | – | 97,683 |
| Richard Aranda Chief Medical Officer | Jun 21, 2021 | Award | +15,000 | – | – | 219,809 |
| Laura Carter Chief Scientific Officer | May 3, 2021 | Award | +10,820 | – | – | 72,683 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Gossamer Bio's stock actually held short. Settlement fails (shares not delivered on time) peaked at 3,535,808 shares on Sep 11, 2026 over the last 90 days.
See a number that looks wrong?